# A Long-term Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis

> **NCT01363713** · PHASE3 · COMPLETED · sponsor: **Santen Pharmaceutical Co., Ltd.** · enrollment: 130 (actual)

## Conditions studied

- Allergic Conjunctivitis

## Interventions

- **DRUG:** DE-114 ophthalmic solution

## Key facts

- **NCT ID:** NCT01363713
- **Lead sponsor:** Santen Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** 2012-09
- **Final completion:** —
- **Target enrollment:** 130 (ACTUAL)
- **Last updated:** 2014-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01363713

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01363713, "A Long-term Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01363713. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*